{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:41:12Z","timestamp":1784374872033,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Letermovir, a novel anti\u2010cytomegalovirus (CMV) agent acts by inhibiting the viral terminase complex and is approved for primary prophylaxis in CMV seropositive patients post allogeneic hematopoietic cell transplantation (HCT). The favorable efficacy and safety profile make it an attractive option for use as secondary prophylaxis in patients at high\u2010risk for CMV reactivation. In this study, we report the efficacy and safety of letermovir secondary prophylaxis after at least one treated episode of CMV reactivation in a cohort of 39 high\u2010risk patients. Thirty two (82%) patients received anti\u2010thymocyte globulin (ATG), 27 (69%) received a combination of ATG and post\u2010transplant cyclophosphamide for graft\u2010versus\u2010host disease (GVHD) prophylaxis. Twenty one patients (54%) received CMV seronegative grafts. In addition, 18 (46%) patients had HLA mismatched unrelated or haploidentical donors while 18 (46%) had active GVHD requiring immunosuppression at the time of commencing secondary prophylaxis. Letermovir was initiated at a median of 47\u2009days (range, 41\u201356) after HCT and was administered for a median duration of 77\u2009days (range, 46\u201390). A single breakthrough CMV reactivation was noted in this high\u2010risk cohort. Four additional episodes of CMV reactivation occurred at a median of 28\u2009days (range, 23\u201359\u2009days) after discontinuation of secondary prophylaxis. The drug was well tolerated and 77% of the cohort completed the planned duration of secondary prophylaxis. None of the patients discontinued treatment due to treatment\u2010related adverse effects. In conclusion, letermovir is effective and well tolerated and may be considered for secondary prophylaxis in patients at high risk for CMV reactivation. Prospective studies are required to validate these findings.<\/jats:p>","DOI":"10.1111\/ejh.14258","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:31:00Z","timestamp":1718955060000},"page":"477-484","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience"],"prefix":"10.1111","volume":"113","author":[{"given":"Nihar","family":"Desai","sequence":"first","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-0113","authenticated-orcid":false,"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-3609","authenticated-orcid":false,"given":"Arjun D.","family":"Law","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Gerbitz","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-4911","authenticated-orcid":false,"given":"Dennis D.","family":"Kim","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-5699","authenticated-orcid":false,"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Novitzky\u2010Basso","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2956-0848","authenticated-orcid":false,"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre  Toronto Canada"},{"name":"Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(20)30707-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05265-11"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12447"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009396"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2854-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14117"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.02.007"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128532"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.431"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad169"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.11.006"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005509"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.191"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.01.011"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.01.027"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01166-w"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13187"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.793"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.10.005"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.354"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101936"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4016-1"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0389-9"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112053252303"},{"issue":"6","key":"e_1_2_8_31_1","first-page":"783","article-title":"CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections","volume":"13","author":"Bacigalupo A","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.01.008"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad709"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:17:20Z","timestamp":1728487040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/ejh.14258"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14258","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"2024-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}